Azita Alipour1, Stephen Gabrielson2, Puja Baldev Patel1. 1. College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA 92831, USA. 2. Health Sciences Library System, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Abstract
BACKGROUND: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia. METHODS: Literature searches were conducted in July 2019 in the PubMed database. RESULTS: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of "mild disease". Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use. CONCLUSIONS: A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology.
BACKGROUND: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia. METHODS: Literature searches were conducted in July 2019 in the PubMed database. RESULTS: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of "mild disease". Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use. CONCLUSIONS: A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology.
Authors: Carl B Roth; Andreas Papassotiropoulos; Annette B Brühl; Undine E Lang; Christian G Huber Journal: Int J Environ Res Public Health Date: 2021-08-05 Impact factor: 3.390
Authors: Olena Litvinova; Elisabeth Klager; Nikolay T Tzvetkov; Oliver Kimberger; Maria Kletecka-Pulker; Harald Willschke; Atanas G Atanasov Journal: Pharmaceuticals (Basel) Date: 2022-08-19